FX-5A is under clinical development by KineMed and currently in Phase I for Atherosclerosis. According to GlobalData, Phase I drugs for Atherosclerosis have a 64% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how FX-5A’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
FX-5A overview
FX-5A is under development for the treatment of atherosclerosis and heart disease. FX-5A is a apolipoprotein A-I high-density lipoprotein mimetic peptide. It is developed by using a platform which is a combination of ultra-sensitive isotopic tracer technology combined with biological expertise enabling to reveal the activity of key causal pathways in diseases. It acts by targeting Apolipoprotein A-I (ApoA-I)
KineMed overview
KineMed is a biotechnology company that develops and commercializes proprietary biomarker platform technology. The company applies its proprietary biomarker platform technology to drug development, prescription, and non-prescription medical diagnostics and the pairing of drugs with diagnostic biomarker tests. It utilizes isotope labeling, mass spectrometry, and other techniques to observe the activity of biochemical pathways, measure molecular fluxes within the pathways, and to monitor the appearance and disappearance of individual proteins and biological biomarkers. Kinmed develops drugs in the therapeutic areas of muscle metabolism, fibrosis, immunity, neurobiology, diabetes, cancer, and others. The company also conducts pharmaceutical research on molecular targets and deconstructed systems. KineMed is headquartered in Emeryville, California, the US.
For a complete picture of FX-5A’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
